Horizon Pharma (HZNP) Tops Q2 EPS by 7c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Brean Capital Remains Bullish on Horizon Pharma (HZNP) Following 2Q Beat
August 10, 2015 6:51 AM EDTBrean Capital reiterated a Buy rating and $40 price target on Horizon Pharma (NASDAQ: HZNP) following the release of its 2Q15 earnings results. revenue was $172.8 million beating consensus estimates of $156.4. Non-GAAP EPS was $0.39 beating consensus' $0.32.
Analyst Difei Yang commented, "Given the pre-announcement of... More
Depomed (DEPO) Sends Letter to Horizon Pharma (HZNP); Will be Open to 'Compelling Proposal'
August 7, 2015 6:32 AM EDTDepomed (NASDAQ: DEPO) has sent the following letter to Horizon Pharma plc (NASDAQ: HZNP) ("Horizon"):
August 7, 2015
Timothy P. Walbert Chairman of the Board, President and Chief Executive OfficerHorizon Pharma plcConnaught House, 1st Floor, 1 Burlington Road Dublin 4, Ireland
Dear Tim,
In our conversation late last week, you stated that Horizon was prepared to increase its proposal and to... More
